Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zithromax · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Azithromycin Monohydrate 600mg Tablets |
| 2 | ACTIVE_COMPARATOR | Zithromax (azithromycin dihydrate)600mg Tablets |
| Name | Type | Description |
|---|---|---|
| Azithromycin Monohydrate 600 mg Tablets | DRUG | - |
| Zithromax (azithromycin dihydrate) 600 mg Tablets | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening Exclusion Criteria: * Positive test results for HIV or hepatitis B or C * Treatment for drug or alcohol dependence * Female subjects who are pregnant or ...
Top 20 of 28 competitors
Zithromax is a small molecule drug being developed for the treatment of Infection. It is currently in Phase 1 clinical development. The drug is being studied for its bioavailability under fed conditions, as part of its development for infectious disease indications.
Zithromax is being developed by Novartis AG, which is publicly traded under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's properties for the treatment of Infection.
Zithromax is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently ongoing.
Zithromax has one completed clinical trial, identified as NCT00865670. This Phase 1 study, titled 'To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions,' enrolled 38 participants and was an active-controlled, randomized trial.
Zithromax is the brand name for azithromycin, a macrolide antibiotic. The clinical trial for Zithromax specifically evaluates azithromycin 600 mg tablets, indicating that Zithromax and azithromycin refer to the same active pharmaceutical ingredient.